Targeted Delivery of Small and Macromolecular Drugs

Site-specific drug delivery and targeting attracts much research interest from both academia and industry, but because of the many challenges faced in the development of these systems, only a handful of targeted therapies have successfully made it into clinical practice. Focusing on the delivery technologies that utilize both systemic and local routes of administration, Targeted Delivery of Small and Macromolecular Drugs brings together field experts who summarize current progress and discuss novel ideas currently being explored to overcome these challenges. The contributors discuss the most promising strategies for drug targeting and also examine targeted drug delivery platforms and technologies at various stages of clinical and preclinical development, including: Active targeting Nucleic acid delivery and targeting Intracellular/organelle-specific strategies Prodrug strategies Organ or tissue-specific drug delivery Drug-polymer conjugates and micelles Stimuli-responsive systems The book demonstrates why targeted delivery is one of the most exciting contributions pharmaceutical sciences can make to drug therapy.

Therapeutic Potential of Targeted Drug DeliveryAjit S. Narang and Ram I. Mahato ACTIVE TARGETINGAntibody Therapies for Liver Malignancy and TransplantationJohn M. Luk and Kwong-Fai WongTransferrin Receptor–Mediated Transcytosis in Intestinal Epithelial Cells for Gastrointestinal Absorption of Protein DrugsNurmamet Amet, Xiaoying Chen, Hsin-Fang Lee, Jennica Zaro, and Wei-Chiang ShenIonizing Radiation for Tumor-Targeted Drug DeliveryRoberto Diaz, Li Zhou, and Dennis E. HallahanNUCLEIC ACID DELIVERY AND TARGETINGRecent Advances in Gene Expression and Delivery SystemsRavikiran Panakanti and Ram I. MahatoCellular Barriers for Nucleic Acid Delivery and TargetingArto UrttiTargeted Delivery Systems of Nonviral Nucleic Acid–Based TherapeuticsGa Yong Shim, Eun-Joong Kim, Rae Sung Chang, Han Young Lee, and Yu-Kyoung OhDelivery and Targeting of Oligonucleotides and siRNANingning Yang and Ram I. MahatoLiposomes for Nonviral Gene DeliveryJiasheng Tu, Yan Shen, Hui Pang, and Yubing Yu INTRACELLULAR/ORGANELLE-PART SPECIFIC STRATEGIESDelivering the Bullet to the Right Intracellular Target: A Cellular Perspective on Drug DeliveryMaria Teresa Tarragó-Trani and Brian StorrieMitochondria-Targeted Drug DeliveryVolkmar Weissig and Gerard G. M. D’SouzaPRODRUG STRATEGIESSite-Specific Prodrug Activation Strategies for Targeted Drug ActionMark D. ErionEnzyme-Activated Prodrug Strategies for Targeted Drug ActionJarkko Rautio, Krista Laine, Lanyan Fang, Bing Han, Kristiina Huttunen, and Duxin SunORGAN- OR TISSUE-SPECIFIC DRUG DELIVERYTargeting Colon and Kidney: Pathophysiological Determinants of Design StrategyAjit S. Narang and Ram I. MahatoPrinciples and Practice of Pulmonary Drug DeliveryVivek Gupta, Chandan Thomas, and Fakhrul AhsanRecent Advances in Ocular Drug Delivery: Role of Transporters, Receptors, and NanocarriersGyan P. Mishra, Ripal Gaudana, Viral M. Tamboli, and Ashim K. Mitra POLYMER–DRUG CONJUGATES AND MICELLESInjectable Polymers for Regional Drug DeliveryRajendra P. Pawar, Niteen R. Shinde, Narsinha M. Andurkar, Satish A. Dake, and Abraham J. DombPolymer–Drug ConjugatesLucienne Juillerat-Jeanneret and Feride CengelliPolymer Micelles for Drug DeliverySungwon Kim and Kinam ParkSTIMULI-RESPONSIVE SYSTEMSMultifunctional Stimuli–Responsive Nanoparticles for Targeted Delivery of Small and Macromolecular TherapeuticsSrinivas Ganta, Arun Iyer, and Mansoor AmijiPhysiological Stress Responsive Gene Regulation Systems for Tissue TargetingHyun Ah Kim and Minhyung Lee

Ajit S. Narang works for the Bristol-Myers Squibb, Co. in New Brunswick, New Jersey, in the biopharmaceutical aspects of drug delivery. He has more than eight years of experience in the pharmaceutical industry in the development of oral dosage forms and drug delivery platforms. In addition to the Bristol-Myers Squibb, Co., he has worked for Ranbaxy Research Labs (currently a subsidiary of Daiichi Sankyo, Japan) in Gurgaon, India, and Morton Grove Pharmaceuticals (currently a subsidiary of Wockhardt USA LLC, Parsippany, New Jersey) in Vernon Hills, Illinois. He has more than 35 publications and three pending patent applications, and has contributed to the development of several marketed drug products. Ram I. Mahato is a full-time professor in the Department of Pharmaceutical Sciences at the University of Health Science Center, Memphis, Tennessee. He was a research assistant professor at the University of Utah, Salt Lake City; a senior scientist at GeneMedicine, Inc., The Woodland, Texas; and a postdoctoral fellow at the University of Southern California in Los Angeles, Washington University in St. Louis, and Kyoto University, Japan. He is an author or coauthor of 79 peer-reviewed articles and book chapters, and has edited/written three books. He is also a special features editor of Pharmaceutical Research and serves on the editorial boards of the Journal of Drug Targeting, Expert Opinion on Drug Delivery, and Transplantation and Risk Management. His research includes delivery and targeting of small molecules, oligonucleotides, siRNA, and genes.